Promedior
5 Great Valley Parkway
Suite 300
Malvern
Pennsylvania
19355
United States
Tel: 610-560-1435
Fax: 610-560-1436
Website: http://www.promedior.com/
Email: info@promedior.com
56 articles about Promedior
-
Promedior Announces Presentation Of Interim Phase 2 Data On PRM-151 In Myelofibrosis At The Upcoming Congress Of European Hematology Association
6/5/2014
-
Tiny Promedior To Present Positive Phase 2 Myelofibrosis Data Next Week
5/30/2014
-
Promedior Announces Presentation Of Interim Phase 2 Data On PRM-151 In Myelofibrosis At American Society of Clinical Oncology
5/15/2014
-
Promedior Attains Patient Enrollment Milestone In Phase 2 Clinical Study Of PRM-151 In Myelofibrosis
1/8/2014
-
Promedior Initiates Phase 2 Clinical Study of PRM-151 in Myelofibrosis
10/9/2013
-
Promedior Adds Howard J. Weisman to Board of Directors
6/19/2013
-
Promedior Presents Encouraging Results From Clinical Study of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis
5/23/2013
-
Promedior to Present Clinical Data on Lead Drug Candidate, PRM-151, in Patients With IPF at the ATS 2013 Annual Meeting
5/16/2013
-
Promedior to Present Clinical Data on Lead Drug Candidate, PRM-151, in Patients with IPF at the ATS 2013 Annual Meeting
5/16/2013
-
Promedior to Present Clinical Data on Lead Drug Candidate, PRM-151, in Patients With IPF at the American Thoracic Society 2013 Annual Meeting
5/16/2013
-
Promedior Opens New Office and Laboratories in Lexington, Mass.
12/17/2012
-
Promedior Closes $24.5 Million Series D
10/15/2012
-
Promedior Appoints Elizabeth Trehu, M.D., as Chief Medical Officer
10/15/2012
-
Promedior Moves Fibrosis Pipeline to Boston, Hires Shire plc Vet as CEO
5/15/2012
-
Promedior Announces Presentation of Preclinical Data at Association for Research in Vision & Ophthalmology Demonstrating that Pentraxin-2 Suppressed Fibrosis, Neovascularization, and Vascular Leakage
5/7/2012
-
Promedior Announces Presentation of Data at Association for Research in Vision & Ophthalmology Demonstrating that Pentraxin-2 Suppresses Fibrosis, Neovascularization, and Vascular Leak in Retinal Disease Models
5/1/2012
-
Promedior Scores $21.5 Million for Fibrotic Diseases
3/8/2012
-
Promedior Receives U.S. Orphan Drug Designation for PRM-151 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
3/8/2012
-
Promedior Presents Preclinical Data at American Association for Study of Liver Diseases Demonstrating That Pentraxin-2 Suppresses Liver Fibrosis and Has a Clear Hepatoprotective Effect
11/7/2011
-
Promedior Announces Presentation of Preclinical Data at AASLD Demonstrating that Pentraxin-2 Suppresses Liver Fibrosis
11/2/2011